NUVL
Nuvalent, Inc.
Nuvalent, Inc. (NUVL) has 29 SEC Form 4 filings (63 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 15, 2026.
The most active filer is Chief Scientific Officer Pelish Henry E. with 3 filings. Insiders have net sold $15.5M over the trailing 6 months.
- Industry:Biotechnology
- CEO:James R. Porter
- Employees:234
- HQ:Cambridge, MA, US
- IPO:2021-07-29
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$15.5M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Pelish Henry E.First in 4 months | Chief Scientific Officer | Sale | 2,111 | $261K | Jul 10 | SEC ↗ |
Porter James RichardFirst in 3 months | President and CEO | Sale | 30,000 | $3.7M | Jul 8 | SEC ↗ |
Balcom AlexandraFirst filing | Chief Financial Officer | Sale | 11,430 | $1.4M | Jul 6 | SEC ↗ |
| Chief Development Officer | Sale | 23,000 | $2.8M | Jul 6 | SEC ↗ | |
Noci DarleneFirst filing | Chief Development Officer | Sale | 5,500 | $679K | Jul 1 | SEC ↗ |
Porter James RichardFirst filing | President and CEO | Sale | 30,000 | $3.1M | Apr 8 | SEC ↗ |
Pelish Henry E.First filing | Chief Scientific Officer | Sale | 30,000 | $2.9M | Mar 16 | SEC ↗ |
Pelish Henry E.First filing | Chief Scientific Officer | Sale | 5,104 | $505K | Mar 16 | SEC ↗ |
Related companies
Nuvalent, Inc. is in the Healthcare sector.